Enhanced Genomics

Executive Summary

Enhanced Genomics is a London-based private company pioneering an integrated 3D multi-omics platform that uncovers causal genetic drivers of common diseases. By revealing the biological mechanisms behind genetic variation, the platform enables rapid identification of high-confidence therapeutic targets. Founded in 2016, the company operates at the intersection of functional genomics and computational biology, aiming to de-risk drug discovery for common diseases. Their technology has the potential to transform how pharmaceutical companies select and validate targets, reducing late-stage attrition and improving pipeline productivity. Despite limited public information on funding or partnerships, the platform's focus on causal biology positions it as a promising player in the precision medicine space.

Upcoming Catalysts (preview)

• Q4 2026First major pharma collaboration or licensing deal40% success
• Q2 2027Series B or growth equity funding round announcement50% success
• Q1 2027Publication of platform validation data in a peer-reviewed journal60% success